title: A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy.
abstract: Twenty patients with advanced cancer for which there was no effective standard therapy or whose disease was refractory to standard therapy were treated with recombinant macrophage colony-stimulating factor (rM-CSF). The rM-CSF was administered by intravenous bolus infusion for 5 consecutive days every other week for 2 treatment weeks. The doses administered ranged from 30 to 33,000 micrograms/m2/day. There was no intrapatient dose escalation. There were minimal to no systemic side effects seen, except for acute dyspnea noted in three patients. The dyspnea was felt to be related to the rate of infusion and did not recur in one patient given additional rM-CSF at a slower infusion rate. The major hematologic effect seen was a mild decrease in platelet count, which began to recover while the patients continued to receive the rM-CSF. The clearance of rM-CSF was dose dependent. Lower doses resulted in a saturable mechanism felt to represent cellular uptake. Clearance at higher doses demonstrated both a first-order mechanism at high serum rM-CSF concentrations, representing renal clearance, as well as a saturable mechanism at low serum concentrations. The maximum mean serum half-life was reached at dose levels of greater than or equal to 3,690 micrograms/m2 and was in the range of 234-258 min. By this route of administration, rises in absolute monocyte count were slight and seen only at doses of greater than or equal to 450 micrograms/m2 during the second therapy week. The maximum tolerated dose was not reached in this study because of lack of availability of rM-CSF.
authors.affiliation: Department of Medicine, State University of New York Health Science Center, Syracuse, New York 13210.
authors.forename: K W
authors.initials: KW
authors.lastname: Zamkoff
authors.forename: J
authors.initials: J
authors.lastname: Hudson
authors.forename: E S
authors.initials: ES
authors.lastname: Groves
authors.forename: A
authors.initials: A
authors.lastname: Childs
authors.forename: M
authors.initials: M
authors.lastname: Konrad
authors.forename: A R
authors.initials: AR
authors.lastname: Rudolph
mesh_terms: D000328:Adult; D000368:Aged; D000920:Antibody-Dependent Cell Cytotoxicity; D002784:Cholesterol / Q000097:blood; D004341:Drug Evaluation; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D015979:Killer Cells, Lymphokine-Activated; D007694:Killer Cells, Natural; D016173:Macrophage Colony-Stimulating Factor / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012137:Respiratory System / Q000187:drug effects; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D011994:Recombinant Proteins; D014280:Triglycerides; D016173:Macrophage Colony-Stimulating Factor; D002784:Cholesterol